File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: External validation of a nomogram to predict survival and benefit of concurrent chemoradiation for stage ii nasopharyngeal carcinoma

TitleExternal validation of a nomogram to predict survival and benefit of concurrent chemoradiation for stage ii nasopharyngeal carcinoma
Authors
KeywordsRadiotherapy
Nasopharyngeal carcinoma
Nomogram
Survival
Chemotherapy
Issue Date2021
Citation
Cancers, 2021, v. 13, n. 17, article no. 4286 How to Cite?
AbstractA nomogram was recently published by Sun et al. to predict overall survival (OS) and the additional benefit of concurrent chemoradiation (CCRT) vs. radiotherapy (RT) alone, in stage II NPC treated with conventional RT. We aimed to assess the predictors of OS and to externally validate the nomogram in the IMRT era. We analyzed stage II NPC patients treated with definitive RT alone or CCRT between 2001 and 2011 under the territory-wide Hong Kong NPC Study Group 1301 study. Clinical parameters were studied using the Cox proportional hazards model to estimate OS. The nomogram by Sun et al. was applied with 1000 times bootstrap resampling to calculate the concordance index, and we compared the nomogram predicted and observed 5-year OS. There were 482 patients included. The 5-year OS was 89.0%. In the multivariable analysis, an age > 45 years was the only significant predictor of OS (HR, 1.98; 95%CI, 1.15–3.44). Other clinical parameters were insignificant, including the use of CCRT (HR, 0.99; 95%CI, 0.62–1.58). The nomogram yielded a concordance index of 0.55 (95% CI, 0.49–0.62) which lacked clinically meaningful discriminative power. The nomogram proposed by Sun et al. should be interpreted with caution when applied to stage II NPC patients in the IMRT era. The benefit of CCRT remained controversial.
Persistent Identifierhttp://hdl.handle.net/10722/303821
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorYip, Pui Lam-
dc.contributor.authorLee, Shing Fung-
dc.contributor.authorChoi, Cheuk Wai Horace-
dc.contributor.authorChan, Po Chung Sunny-
dc.contributor.authorCheung, Ka Wai Alice-
dc.contributor.authorChow, Chung Hang James-
dc.contributor.authorCheung, Ka Man-
dc.contributor.authorLai, Wing Yu Jessica-
dc.contributor.authorLee, Ho Fun Victor-
dc.contributor.authorLam, Ka On-
dc.contributor.authorChiang, Chi Leung-
dc.contributor.authorWong, Chun Yin Edwin-
dc.contributor.authorPoon, Ming Chun Darren-
dc.contributor.authorTong, Macy-
dc.contributor.authorAu, Kwok Hung-
dc.contributor.authorNg, Wai Tong-
dc.contributor.authorNgan, Kai Cheong Roger-
dc.contributor.authorLee, Wing Mui Anne-
dc.contributor.authorTung, Yuk Stewart-
dc.date.accessioned2021-09-15T08:26:05Z-
dc.date.available2021-09-15T08:26:05Z-
dc.date.issued2021-
dc.identifier.citationCancers, 2021, v. 13, n. 17, article no. 4286-
dc.identifier.urihttp://hdl.handle.net/10722/303821-
dc.description.abstractA nomogram was recently published by Sun et al. to predict overall survival (OS) and the additional benefit of concurrent chemoradiation (CCRT) vs. radiotherapy (RT) alone, in stage II NPC treated with conventional RT. We aimed to assess the predictors of OS and to externally validate the nomogram in the IMRT era. We analyzed stage II NPC patients treated with definitive RT alone or CCRT between 2001 and 2011 under the territory-wide Hong Kong NPC Study Group 1301 study. Clinical parameters were studied using the Cox proportional hazards model to estimate OS. The nomogram by Sun et al. was applied with 1000 times bootstrap resampling to calculate the concordance index, and we compared the nomogram predicted and observed 5-year OS. There were 482 patients included. The 5-year OS was 89.0%. In the multivariable analysis, an age > 45 years was the only significant predictor of OS (HR, 1.98; 95%CI, 1.15–3.44). Other clinical parameters were insignificant, including the use of CCRT (HR, 0.99; 95%CI, 0.62–1.58). The nomogram yielded a concordance index of 0.55 (95% CI, 0.49–0.62) which lacked clinically meaningful discriminative power. The nomogram proposed by Sun et al. should be interpreted with caution when applied to stage II NPC patients in the IMRT era. The benefit of CCRT remained controversial.-
dc.languageeng-
dc.relation.ispartofCancers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectRadiotherapy-
dc.subjectNasopharyngeal carcinoma-
dc.subjectNomogram-
dc.subjectSurvival-
dc.subjectChemotherapy-
dc.titleExternal validation of a nomogram to predict survival and benefit of concurrent chemoradiation for stage ii nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/cancers13174286-
dc.identifier.pmid34503096-
dc.identifier.pmcidPMC8428339-
dc.identifier.scopuseid_2-s2.0-85113329878-
dc.identifier.hkuros325164-
dc.identifier.volume13-
dc.identifier.issue17-
dc.identifier.spagearticle no. 4286-
dc.identifier.epagearticle no. 4286-
dc.identifier.eissn2072-6694-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats